Partial Seizures With or Without Secondary Generalization Clinical Trial
Official title:
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization
Male and female patients between 16 and 70 years of age who are diagnosed with epilepsy with
partial seizures and are taking up to 3 medications for this medical condition will take
part in this research study at approximately 80 different locations in Australia and Europe.
The purpose of this study is to evaluate the effectiveness, safety and tolerability of
consistent dosages of study drug (lacosamide) taken orally twice a day for about 4 months.
Each patient who qualifies and chooses to participate in the study will receive placebo
(inactive drug) or gradually increasing doses of lacosamide (SPM 927) up to the target dose
of 200mg/day or 400mg/day. The target dose or placebo will be maintained for 12 weeks.
The study clinic visits will include a medical history and physical exam, ECG, blood and
urine sample collection, and completion of a seizure diary.
Patients who complete the study may enroll in an extension trial and receive active study
drug.
n/a
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03685630 -
A Study to Evaluate the Safety and Tolerability of Intravenous Brivaracetam (BRV) as Replacement for Oral Brivaracetam in Japanese Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
|
Phase 3 | |
| Enrolling by invitation |
NCT03250377 -
A Study to Test the Safety/ Efficacy of Brivaracetam (BRV) Used as Adjunctive Treatment in Subjects >=16 Years of Age With Partial Seizures With or Without Secondary Generalization
|
Phase 3 | |
| Completed |
NCT03083665 -
A Study to Evaluate the Efficacy and Safety of Brivaracetam in Study Participants (>=16 to 80 Years of Age) With Epilepsy
|
Phase 3 |